ArticleVaccines2021
Willingness to Pay for a Hypothetical COVID-19 Vaccine in the United States: A Contingent Valuation Approach.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Do Patients Value the Service Provided by Physicians Who Overbill? A Willingness-to-Pay Study Using French Survey Data.Health economics · 2026Article
- Preventing firearm-related deaths and the public good: a contingent valuation study in California.Health affairs scholar · 2026Article
- Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country.PharmacoEconomics - open · 2024Article
- Sociodemographic determinants of vaccination and willingness to pay for COVID-19 vaccines in Hungary, results of a cross-sectional online questionnaire.BMC public health · 2024Article
- Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel.Israel journal of health policy research · 2024Article
- An examination of willingness to participate and willingness to pay for a universal school food program in the Canadian context.Public health nutrition · 2023Article
- Comparison of SARS-CoV-2 Vaccination Skepticism, Reasons, and Concerns Between Mass Vaccination Centers and General Practices in Germany 2021.Patient preference and adherence · 2023Article
- Willingness to pay for COVID-19 vaccines: Applying the health belief model.Research in social & administrative pharmacy : RSAP · 2023Article
- Willingness to pay for a COVID-19 vaccine and its associated determinants in Iran.Frontiers in public health · 2023Article
- Willingness to Pay (WTP) for COVID-19 Vaccine Booster Dose and Its Determinants in Indonesia.Infectious disease reports · 2022Article
- Willingness to pay for HPV vaccine among female health care workers in a Chinese nationwide survey.BMC health services research · 2022Article
- Acceptance and willingness to pay under the different COVID-19 vaccines: A contingent valuation method.Research in social & administrative pharmacy : RSAP · 2022Article
- Article
- Lockdown design: which features of lockdowns are most important to COVID-19 experts?Journal of the Royal Society of New Zealand · 2022Article
- Health-care Workers' Willingness to Pay for COVID-19 Vaccines in Eastern Ethiopia: Using Contingent Valuation Method.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China.Frontiers in pharmacology · 2022Article
- "Please, you go first!" preferences for a COVID-19 vaccine among adults in the Netherlands.Social science & medicine (1982) · 2022Article
- Factors associated with acceptance of COVID-19 vaccine among University health sciences students in Northwest Nigeria.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Our objective was to estimate the individual willingness to pay (WTP) for a COVID-19 vaccine and evaluate its predictors in the United States. A double-bounded dichotomous choice contingent valuation with open-ended question technique was implemented based on the responses to a national survey administered during the first week of November 2020. The final sample size was 1285. The results showed that individual WTP values increased with income, whether a household member had any pre-existing condition, and perceived threat of the virus. The vaccine efficacy rate and duration of protection were found to be important factors for the respondents. The mean WTP for a vaccine with a 95 percent efficacy rate and 3-year protection (US$318.76) was approximately 35 percent greater than the vaccine with a 50 percent efficacy rate and 1-year protection (US$236.85). The initial aggregate direct benefit of the current vaccination program was estimated to be between 20 and 35.6 billion US dollars depending on the vaccine protection duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.